OKYO Pharma Limited (“OKYO” or the “Company”) to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), the…
Zynova Tech Launches the Title Industry’s First Automated Workshare Platform for Compliant, Multi-Jurisdictional Order Flow
Masar Destination Achieves LEED for Communities Gold Certification
Sir Ivan Releases “Love Is The Piece”